337 related articles for article (PubMed ID: 35169082)
21. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
22. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
23. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
24. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
25. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
Labreche K; Kinnersley B; Berzero G; Di Stefano AL; Rahimian A; Detrait I; Marie Y; Grenier-Boley B; Hoang-Xuan K; Delattre JY; Idbaih A; Houlston RS; Sanson M
Acta Neuropathol; 2018 May; 135(5):743-755. PubMed ID: 29460007
[TBL] [Abstract][Full Text] [Related]
26. Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study.
Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280
[TBL] [Abstract][Full Text] [Related]
27. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
28. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR; Wen PY; Lang-Orsini M; Chukwueke UN
JAMA Oncol; 2022 Oct; 8(10):1493-1501. PubMed ID: 36006639
[TBL] [Abstract][Full Text] [Related]
29. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
; Brat DJ; Verhaak RG; Aldape KD; Yung WK; Salama SR; Cooper LA; Rheinbay E; Miller CR; Vitucci M; Morozova O; Robertson AG; Noushmehr H; Laird PW; Cherniack AD; Akbani R; Huse JT; Ciriello G; Poisson LM; Barnholtz-Sloan JS; Berger MS; Brennan C; Colen RR; Colman H; Flanders AE; Giannini C; Grifford M; Iavarone A; Jain R; Joseph I; Kim J; Kasaian K; Mikkelsen T; Murray BA; O'Neill BP; Pachter L; Parsons DW; Sougnez C; Sulman EP; Vandenberg SR; Van Meir EG; von Deimling A; Zhang H; Crain D; Lau K; Mallery D; Morris S; Paulauskis J; Penny R; Shelton T; Sherman M; Yena P; Black A; Bowen J; Dicostanzo K; Gastier-Foster J; Leraas KM; Lichtenberg TM; Pierson CR; Ramirez NC; Taylor C; Weaver S; Wise L; Zmuda E; Davidsen T; Demchok JA; Eley G; Ferguson ML; Hutter CM; Mills Shaw KR; Ozenberger BA; Sheth M; Sofia HJ; Tarnuzzer R; Wang Z; Yang L; Zenklusen JC; Ayala B; Baboud J; Chudamani S; Jensen MA; Liu J; Pihl T; Raman R; Wan Y; Wu Y; Ally A; Auman JT; Balasundaram M; Balu S; Baylin SB; Beroukhim R; Bootwalla MS; Bowlby R; Bristow CA; Brooks D; Butterfield Y; Carlsen R; Carter S; Chin L; Chu A; Chuah E; Cibulskis K; Clarke A; Coetzee SG; Dhalla N; Fennell T; Fisher S; Gabriel S; Getz G; Gibbs R; Guin R; Hadjipanayis A; Hayes DN; Hinoue T; Hoadley K; Holt RA; Hoyle AP; Jefferys SR; Jones S; Jones CD; Kucherlapati R; Lai PH; Lander E; Lee S; Lichtenstein L; Ma Y; Maglinte DT; Mahadeshwar HS; Marra MA; Mayo M; Meng S; Meyerson ML; Mieczkowski PA; Moore RA; Mose LE; Mungall AJ; Pantazi A; Parfenov M; Park PJ; Parker JS; Perou CM; Protopopov A; Ren X; Roach J; Sabedot TS; Schein J; Schumacher SE; Seidman JG; Seth S; Shen H; Simons JV; Sipahimalani P; Soloway MG; Song X; Sun H; Tabak B; Tam A; Tan D; Tang J; Thiessen N; Triche T; Van Den Berg DJ; Veluvolu U; Waring S; Weisenberger DJ; Wilkerson MD; Wong T; Wu J; Xi L; Xu AW; Yang L; Zack TI; Zhang J; Aksoy BA; Arachchi H; Benz C; Bernard B; Carlin D; Cho J; DiCara D; Frazer S; Fuller GN; Gao J; Gehlenborg N; Haussler D; Heiman DI; Iype L; Jacobsen A; Ju Z; Katzman S; Kim H; Knijnenburg T; Kreisberg RB; Lawrence MS; Lee W; Leinonen K; Lin P; Ling S; Liu W; Liu Y; Liu Y; Lu Y; Mills G; Ng S; Noble MS; Paull E; Rao A; Reynolds S; Saksena G; Sanborn Z; Sander C; Schultz N; Senbabaoglu Y; Shen R; Shmulevich I; Sinha R; Stuart J; Sumer SO; Sun Y; Tasman N; Taylor BS; Voet D; Weinhold N; Weinstein JN; Yang D; Yoshihara K; Zheng S; Zhang W; Zou L; Abel T; Sadeghi S; Cohen ML; Eschbacher J; Hattab EM; Raghunathan A; Schniederjan MJ; Aziz D; Barnett G; Barrett W; Bigner DD; Boice L; Brewer C; Calatozzolo C; Campos B; Carlotti CG; Chan TA; Cuppini L; Curley E; Cuzzubbo S; Devine K; DiMeco F; Duell R; Elder JB; Fehrenbach A; Finocchiaro G; Friedman W; Fulop J; Gardner J; Hermes B; Herold-Mende C; Jungk C; Kendler A; Lehman NL; Lipp E; Liu O; Mandt R; McGraw M; Mclendon R; McPherson C; Neder L; Nguyen P; Noss A; Nunziata R; Ostrom QT; Palmer C; Perin A; Pollo B; Potapov A; Potapova O; Rathmell WK; Rotin D; Scarpace L; Schilero C; Senecal K; Shimmel K; Shurkhay V; Sifri S; Singh R; Sloan AE; Smolenski K; Staugaitis SM; Steele R; Thorne L; Tirapelli DP; Unterberg A; Vallurupalli M; Wang Y; Warnick R; Williams F; Wolinsky Y; Bell S; Rosenberg M; Stewart C; Huang F; Grimsby JL; Radenbaugh AJ; Zhang J
N Engl J Med; 2015 Jun; 372(26):2481-98. PubMed ID: 26061751
[TBL] [Abstract][Full Text] [Related]
31. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
32. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
33. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
34. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
35. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Malzkorn B; Reifenberger G
Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
[TBL] [Abstract][Full Text] [Related]
36. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
[No Abstract] [Full Text] [Related]
37. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
38.
Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
[TBL] [Abstract][Full Text] [Related]
39. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Performance of [
Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
